-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nisevokitug in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nisevokitug in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug...
-
Product Insights
Pancreatic Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Pancreatic Tumor - Drugs In Development, 2023’, provides an overview of the Pancreatic Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pancreatic Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-8189
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tavokinogene Telseplasmid in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tavokinogene Telseplasmid in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tavokinogene Telseplasmid in Metastatic Melanoma Drug Details:Tavokinogene telseplasmid (DNA IL-12, Interleukin-12) is...
-
Product Insights
Inhalable Drug Delivery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Inhalable Drug Delivery Pipeline Market Report Overview An inhalable drug delivery device is meant to administer medications that are to be inhaled deeply into the lungs. Drugs are delivered either by the nasal or oral respiratory route. The Inhalable Drug Delivery pipeline market research report provides comprehensive information about the inhalable drug delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials that are in progress. Key Segments ·       ...
-
Company Profile
NewOncoSec Medical Inc – Company Profile
OncoSec Medical Inc (OncoSec), a subsidiary of Grand Pharmaceutical Group Ltd, is a biotechnology company that focusses on designing and developing gene therapies, therapeutics and medical approaches. It offers services to stimulate body’s immune system and attack cancer. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. The company also identifies and develops novel immune-targeting agents for use with the immunogenicity platform. It conducts pre-clinical and clinical studies targeting various...
Add to Basket -
Thematic Analysis
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...
-
Product Insights
OncoSec Medical Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our OncoSec Medical Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. OncoSec Medical Inc (OncoSec) is a biotechnology company. The company offers services to stimulate body’s immune system and attack cancer. Its lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative...
-
Sector Analysis
Immuno-Oncology (IO) – Thematic Intelligence
Accessing the in-depth insight from the ‘Immuno-Oncology Market' report will allow you to – Obtain immuno-oncology market assessment and forecast across multiple regions Gain insight into promising early-stage approaches. Our indication specific forecast models answer questions such as – What is the target patient pool for cell & gene therapies in each cancer indication? Which patient groups are more likely to receive these therapies? What does the cell & gene therapy clinical stage pipeline look like in each cancer indication What...